Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Yee-Sin Leo and Barnaby Young.
Yee-Sin Leo
Connection Strength
1.887
Barnaby Young
  1. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2021 Aug 23.
    View in: PubMed
    Score: 0.241
  2. Diagnostic performance of COVID-19 serological assays during early infection: A systematic review and meta-analysis of 11 516 samples. Influenza Other Respir Viruses. 2021 07; 15(4):529-538.
    View in: PubMed
    Score: 0.233
  3. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. Clin Infect Dis. 2020 11 19; 71(16):2199-2206.
    View in: PubMed
    Score: 0.229
  4. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Transl Immunology. 2020; 9(7):e1159.
    View in: PubMed
    Score: 0.224
  5. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 04 21; 323(15):1488-1494.
    View in: PubMed
    Score: 0.220
  6. Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. EMBO Mol Med. 2021 06 07; 13(6):e14045.
    View in: PubMed
    Score: 0.059
  7. Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Sci Rep. 2021 04 05; 11(1):7477.
    View in: PubMed
    Score: 0.059
  8. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infect Dis. 2021 Jun; 8(6):ofab156.
    View in: PubMed
    Score: 0.059
  9. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021 Jun; 2(6):e240-e249.
    View in: PubMed
    Score: 0.058
  10. Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. Clin Transl Immunology. 2021; 10(2):e1241.
    View in: PubMed
    Score: 0.058
  11. Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. Cell Rep Med. 2021 02 16; 2(2):100193.
    View in: PubMed
    Score: 0.058
  12. Association of Higher Body Mass Index With Severe Coronavirus Disease 2019 (COVID-19) in Younger Patients. Clin Infect Dis. 2020 11 19; 71(16):2300-2302.
    View in: PubMed
    Score: 0.057
  13. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nat Commun. 2020 10 16; 11(1):5243.
    View in: PubMed
    Score: 0.057
  14. Radiographic features of COVID-19 based on an initial cohort of 96 patients in Singapore. Singapore Med J. 2021 09; 62(9):458-465.
    View in: PubMed
    Score: 0.056
  15. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020 Aug; 58:102911.
    View in: PubMed
    Score: 0.056
  16. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020 06 01; 11(1):2806.
    View in: PubMed
    Score: 0.055
  17. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nat Commun. 2020 05 29; 11(1):2800.
    View in: PubMed
    Score: 0.055
  18. Absence of contamination of personal protective equipment (PPE) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infect Control Hosp Epidemiol. 2020 05; 41(5):614-616.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.